You are here

Home » Content

Peritonit Dışı İnfeksiyonlar

Nonperitoneal Infections

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2007
Author NameUniversity of AuthorFaculty of Author
Bookmark/Search this post with
Abstract (Original Language): 
Son dönem kronik böbrek yetmezliğinin tedavisinde giderek daha yaygın bir seçenek olan periton diyalizinin en Önemli komplikasyonları enfeksiyonlardır. Peritonit tedavisinde meydana gelen gelişmeler ve eğitimle peritonit sıklığında azalma görülmesine rağmen, peritonit dışı enfeksiyöz komplikasyonları olan çıkış yeri ve tünel enfeksiyonlarının sıklığında azalma görülmemektedir. Bu enfeksiyonlar halen Önemli morbidite, peritonit oluşumu ve kate-ter kaybına neden olmaktadır. CAPD ve CCPD için çıkış yeri ve tünel enfeksiyonlarının insidansı 0.6 epizot/hasta yılıdır (1). Kateter değiştirilmesi İnsidansı ise bu hastalarda CAPD için 0.2/hasta yılı, CCPD hastaları için 0.3/hasta yılıdır. Aletli periton diyalizi (APD) için ise bu oranlar 0.41-0.62 epizot/hasta yılı olarak değişmektedir (2). Yaş ve diyaliz süresinin anması tünel ve çıktş yeri enfeksiyonu insidansını azaltmakladır (3).
FULL TEXT (PDF): 
PDF icon arastrmx_172977_16_pp_52-56.pdf
  • 1
52-56
  • Turkish

REFERENCES

References: 

1. Lindblad AS, Novak JW, Nolplı KD, et al. Co m plication,s of treatment. İn Final Repon of the National CAPD Registry of the National Institutes of Health. 1988:4-1 -4-13.
2. Bıırkarl JM, Jordan JR, Durnell TA, Case LD. Comparison of exit-site infections in disconnect versus nondisconnect systems for peritoneal dialysis. Peril Dial Int 1992;12:317-20,
3. Holley JL, Bernardini J, Piraino B, Continuous cycling Peritoneal dialysis is associated with lower rates of catheter
infections than continuous ambulatory Peritoneal dialysis. Am J Kidney Dis 1990;16:133-6.
4. Gloor HJ, Nichols WK, Sorkin Ml, et al. Peritoneal access and related complications in continuous ambulatory peritoneal dialysis. Am J Med 1983;74:593-8.
5. Piraino B, Bailie GR, Bernardini J, et al. Peritoneal Dialysis-Related Infections Recommendations: 2005 Update. Peritoneal Dialysis International, Vol.25, pp. 107-131.
6. Schaefer F, Klaus G, Muller-Wiefel DE, Mehis O. Intermittent versus continuous intraperitoneal gycopeplide/ceilazidime treatment in children with Peritoneal dialysis-associaled peritonitis. The Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS). J Am Soc. Nephrol 1999;10(l>:136-45.
7. Gloor HJ, Nichols WK, Sorkin MI, et al. Peritoneal Access and related complications in continuous ambulatory Peritonea! dialysis. Am J Med 1983;74:593-8.
8. Piraino B, Bernardini J, Sorkin M. Catheter infections as a factor in the transfer of continuous ambulatory Peritoneal dialysis patients to hemodialysis. Am J Kidney Dis 1989;13:365-9.
9. Twardowski ZJ, Nichols WK. Peritoneal dialysis Access and exit-site care including surgical aspects; Gokal R, Khanna R, Krediet R and Nolp K(eds): Textbook of Peritoneal Dialysis, 2nd Edition. Dordrecht, Kluwer Academic Publishers, 2000, pp 307-362.
10. Luzar MMA, Brown CB, Balf D, Hill L, Issad B, Monnier B, et al. Exit-site care and exit-site infection in continuous ambulatory peritoneal dialysis(CAPD): results of a randomized multicenter trial. Peril Dial Int 1990;10(l);25-9.
11. Herwaldt LA, Boyken LD, Coffman S, Hochstetler l„ Flanigan MJ. Sources of Staphylococcus aureus for patients on continuous ambulatory peritoneal dialysis. Peril Dial lni 2003;23(3):237-41.
12. Lobbedez T, Gardam M, Dedier H, Burdzy D, Chu M, Ezatt S, et al. Routine use of mupirocin at the peritoneal catheter exit-site and mupirocin resistance: still low after 7 years. Nephrol Dial Transplant 2004;19:3140-3.
13. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdes F. Mupirocin resistance after long-temi use of Staphylococcus aureus colonisation in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002; 39(2): 337-41,
14. Bernardini J, Bender F, Florio T, Sloand J, Palm Montalbano I., Fried L, et al. Randomized double blinded trial of antibiotic exit site cream for the prevention of exit site infection in perݬtoneal dialysis patients. J Am Soc Nephrol 2(105; 16:539-45.
15. Montenegro J, Saracho R, Aguirre R, Martinez I, Iribar I, OcharanJ. Exit-site care with ciprofloxacin otologic solution prevents polyurethane catheter infection in peritoneal dialysis patients. Peril Dial Int 2000;20(2):209-14.
16. Flanigan M, Gokal R: Peritoneal catheters and exit-site practices toward optimum peritoneal access: A review of current developments. Perit Dial Int 2005;Vol 25: pp 132-139-

Thank you for copying data from http://www.arastirmax.com